{"id": "367950", "url": "https://fevir.net/resources/Evidence/367950", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/comparative-evidence"], "versionId": "26", "lastUpdated": "2025-08-18T13:22:42.074Z"}, "name": "NCT03640312_secondaryOutcomeMeasure_7_OutcomeAnalysis_9_BetweenGroupAnalysis_OG000_OG001", "title": "Health-related Quality of Life at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312", "author": [{"name": "Computable Publishing\u00ae: ClinicalTrials.gov-to-FEvIR Converter"}], "citeAs": "Health-related Quality of Life at 12 weeks Statistical Analysis for QUARTET LDQT vs Candesartan in NCT03640312 [Database Entry: FHIR Evidence Resource]. Contributors: Computable Publishing\u00ae: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 367950. Revised 2025-08-18. Available at: https://fevir.net/resources/Evidence/367950. Computable resource at: https://fevir.net/resources/Evidence/367950#json.", "status": "active", "contact": [{"telecom": [{"value": "support@computablepublishing.com", "system": "email"}]}], "copyright": "https://creativecommons.org/licenses/by-nc-sa/4.0/", "extension": [{"url": "http://hl7.org/fhir/uv/ebm/StructureDefinition/artifact-publication-status", "valueCodeableConcept": {"coding": [{"code": "active", "system": "http://terminology.hl7.org/CodeSystem/cited-artifact-status-type", "display": "Active"}]}}], "publisher": "Computable Publishing LLC", "statistic": [{"note": [{"text": "Outcome Analysis NonInferiority Type: Superiority"}], "quantity": {"unit": "score on a scale", "value": 0.55}, "statisticType": {"text": "Mean Difference (Net)"}, "attributeEstimate": [{"type": {"coding": [{"code": "STATO:0000037", "system": "https://fevir.net/sevco", "display": "standard error of the mean"}]}, "quantity": {"unit": "score on a scale", "value": 1.88}}, {"note": [{"text": "Adjusted for baseline mental health T score"}], "type": {"coding": [{"code": "C44185", "system": "http://terminology.hl7.org/CodeSystem/attribute-estimate-type", "display": "P-value"}]}, "quantity": {"value": 0.77}}, {"note": [{"text": "CI Number of Sides: 2-Sided"}], "type": {"coding": [{"system": "http://terminology.hl7.org/CodeSystem/attribute-estimate-type", "code": "C53324", "display": "Confidence interval"}]}, "level": 0.95, "range": {"low": {"unit": "score on a scale", "value": -3.22}, "high": {"unit": "score on a scale", "value": 4.32}}}], "modelCharacteristic": [{"code": {"text": "ANCOVA"}}]}], "identifier": [{"type": {"text": "FEvIR Object Identifier", "coding": [{"system": "http://terminology.hl7.org/CodeSystem/v2-0203", "code": "ACSN", "display": "Accession ID"}]}, "value": "367950", "system": "https://fevir.net/FOI", "assigner": {"display": "Computable Publishing LLC"}}, {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-secondaryOutcomeMeasure-7-OutcomeAnalysis-9-BetweenGroupAnalysis-OG000-OG001", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}], "description": "Statistical test for difference in Mental Health T Score", "resourceType": "Evidence", "variableDefinition": [{"note": [{"text": "Data are available on only 28 participants in the intervention group for the mental health T score."}], "intended": {"type": "Group", "reference": "Group/367881", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312 Eligibility Criteria", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, "variableRole": "population"}, {"observed": {"display": "Group Assignment: Patients randomized to the intervention arm took a once daily ultra-low-dose quadruple combination therapy (QUARTET LDQT). The LDQT is an overencapsulated combination pill comprising four types of blood pressure lowering medications each at \u00bc standard doses. QUARTET includes candesartan 2mg, amlodipine besylate 1.25mg, indapamide 0.625mg, and bisoprolol 2.5mg. The individual components are currently approved and marketed within the United States.\n\nQUARTET LDQT: Ultra-low-dose combination therapy comprising four different blood pressure lowering drugs at 1/4 dosages. Taken once daily for 12 weeks. vs. Patients randomized to the comparison arm took a once daily 8mg candesartan.\n\nCandesartan: Standard monotherapy of 8mg candesartan. Taken once daily for 12 weeks."}, "description": "Group Assignment: QUARTET LDQT vs. Candesartan", "variableRole": "exposure", "comparatorCategory": "Candesartan"}, {"observed": {"type": "EvidenceVariable", "display": "Health-related Quality of Life at 12 weeks (NCT03640312)", "reference": "EvidenceVariable/367890", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03640312-secondaryOutcome-7", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, "variableRole": "outcome"}]}